Adenovirus-vectored Ebola vaccines

Expert Review of Vaccines

Volumn 14, Issue 10, 2015, Pages 1347-1357

  Gilbert, Sarah C ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

clinical trials; Ebola virus disease; outbreak pathogen; replication deficient adenoviral vector; response to vaccination; simian adenoviral vector; vaccination

Indexed keywords

ADENOVIRUS VECTOR; DNA VACCINE; EBOLA VACCINE; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

DNA IMMUNIZATION; DRUG EFFICACY; DRUG SAFETY; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; EPIDEMIC; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION CONTROL; INFECTION PREVENTION; NONHUMAN; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; REVIEW; VACCINATION; ADENOVIRIDAE; AFRICA SOUTH OF THE SAHARA; DISEASE OUTBREAKS; GENETICS; HEMORRHAGIC FEVER, EBOLA; IMMUNOLOGY; VIROLOGY;

ADENOVIRIDAE; AFRICA SOUTH OF THE SAHARA; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DISEASE OUTBREAKS; EBOLA VACCINES; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; HUMANS; VACCINATION;

EID: 84941808980     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2015.1077122     Document Type: Review

References (74)

1. Feldmann H, Slenczka W, Klenk HD. Emerging and reemerging of filoviruses. Arch Virol 1996; 11: 77-100.
2. Feldmann H, Klenk HD. Filoviruses. In: Baron S.,. Editor. Medical microbiology. The University of Texas Medical Branch at Galveston, Galveston TX, 1996
3. Le Guenno B, Formenty P, Wyers M, et al. Isolation and partial characterisation of a new strain of Ebola virus. Lancet 1995; 345 (8960): 1271-4
4. Towner JS, Sealy TK, Khristova ML, et al. Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog 2008; 4 (11): e1000212
5. Rouquet P, Froment JM, Bermejo M, et al. Wild animal mortality monitoring and human Ebola outbreaks, Gabon and Republic of Congo, 2001-2003. Emerg Infect Dis 2005; 11 (2): 283-90
6. Rewar S, Mirdha D. Transmission of Ebola virus disease: An overview. Annals of global health 2014; 80 (6): 444-51
7. WHO. Ebola situation report-27 May 2015. http://apps.who.int/ebola/current-situation/ebola-situation-report-27-may-2015
8. Mackay IM, Arden KE. Ebola virus in the semen of convalescent men. Lancet Infect Dis 2015; 15 (2): 149-50
9. Varkey JB, Shantha JG, Crozier I, et al. Persistence of Ebola virus in ocular fluid during convalescence. N Engl J Med 2015; 372 (25): 2423-7
10. Lasaro MO, Ertl HC. New insights on adenovirus as vaccine vectors. Mol Ther 2009; 17 (8): 1333-9
11. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372 (9653): 1881-93
12. Gray G, Buchbinder S, Duerr A. Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine. Curr Opin HIV AIDS 2010; 5 (5): 357-61
13. Stephenson KE, Hural J, Buchbinder SP, et al. Preexisting adenovirus seropositivity is not associated with increased HIV-1 acquisition in three HIV-1 vaccine efficacy trials. J Infect Dis 2012; 205 (12): 1806-10
14. Benlahrech A, Harris J, Meiser A, et al. Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. Proc Natl Acad Sci USA 2009; 106 (47): 19940-5
15. Hutnick NA, Carnathan DG, Dubey SA, et al. Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4+ T cells. Nat Med 2009; 15 (8): 876-8
16. Gentile G, Venditti M, Micozzi A, et al. Cryptosporidiosis in patients with hematologic malignancies. Rev Infect Dis 1991; 13 (5): 842-6
17. Masek-Hammerman K, Li H, Liu J, et al. Mucosal trafficking of vector-specific CD4+ T lymphocytes following vaccination of rhesus monkeys with adenovirus serotype 5. J Virol 2010; 84 (19): 9810-16
18. Cheng C, Wang L, Gall JG, et al. Decreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccination. PLoS One 2012; 7 (4): e33969
19. Perreau M, Pantaleo G, Kremer EJ. Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells. J Exp Med 2008; 205 (12): 2717-25
20. Sumida SM, Truitt DM, Lemckert AA, et al. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol 2005; 174 (11): 7179-85
21. Kobinger GP, Feldmann H, Zhi Y, et al. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology 2006; 346 (2): 394-401
22. Geisbert TW, Bailey M, Hensley L, et al. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. J Virol 2011; 85 (9): 4222-33
23. Alcock R, Cottingham MG, Rollier CS, et al. Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass. Sci Transl Med 2010; 2 (19): 19-12
24. Schooley RT, Spritzler J, Wang H, et al. AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein. J Infect Dis 2010; 202 (5): 705-16
25. OHara GA, Duncan CJ, Ewer KJ, et al. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis 2012; 205 (5): 772-81
26. Kimani D, Jagne YJ, Cox M, et al. Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations. Mol Ther 2014; 22 (11): 1992-2003
27. Antrobus RD, Coughlan L, Berthoud TK, et al. Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens. Mol Ther 2014; 22 (3): 668-74
28. Lubaroff DM, Konety BR, Link B, et al. Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results. Clin Cancer Res 2009; 15 (23): 7375-80
29. Vellinga J, Smith JP, Lipiec A, et al. Challenges in manufacturing adenoviral vectors for global vaccine product deployment. Hum Gene Ther 2014; 25 (4): 318-27
30. Xu L, Sanchez A, Yang Z, et al. Immunization for Ebola virus infection. Nat Med 1998; 4 (1): 37-42
31. Vanderzanden L, Bray M, Fuller D, et al. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology 1998; 246 (1): 134-44
32. Sullivan NJ, Sanchez A, Rollin PE, et al. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000; 408 (6812): 605-9
33. Hanke T, Blanchard TJ, Schneider J, et al. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine 1998; 16 (5): 439-45
34. Schneider J, Gilbert SC, Blanchard TJ, et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 1998; 4 (4): 397-402
35. Sullivan NJ, Geisbert TW, Geisbert JB, et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 2003; 424 (6949): 681-4
36. Sullivan NJ, Geisbert TW, Geisbert JB, et al. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med 2006; 3 (6): e177
37. Dudareva M, Andrews L, Gilbert SC, et al. Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy. Vaccine 2009; 27 (27): 3501-4
38. Colloca S, Barnes E, Folgori A, et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med 2012; 4 (115): 115-112
39. Stanley DA, Honko AN, Asiedu C, et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med 2014; 20 (10): 1126-9
40. Swadling L, Capone S, Antrobus RD, et al. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci Transl Med 2014; 6 (261): 261-153
41. Capone S, Reyes-Sandoval A, Naddeo M, et al. Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates. Vaccine 2010; 29 (2): 256-65
42. Wang D, Raja NU, Trubey CM, et al. Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus. J Virol 2006; 80 (6): 2738-46
43. Pratt WD, Wang D, Nichols DK, et al. Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector. Clin Vaccine Immunol 2010; 17 (4): 572-81
44. Richardson JS, Yao MK, Tran KN, et al. Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine. PLoS One 2009; 4 (4): e5308
45. Richardson JS, Wong G, Pillet S, et al. Evaluation of Different Strategies for Post-Exposure Treatment of Ebola Virus Infection in Rodents. J Bioterror Biodef 2011;(Suppl 1): pii: 007
46. Wong G, Richardson JS, Pillet S, et al. adenovirus-vectored vaccine provides postexposure protection to Ebola virus-infected nonhuman primates. J Infect Dis 2015. [Epub ahead of print]
47. Haas CN. On the quarantine period for ebola virus. PLoS currents 2014; 6
48. Wong G, Richardson JS, Cutts T, et al. Intranasal immunization with an adenovirus vaccine protects guinea pigs from Ebola virus transmission by infected animals. Antiviral Res 2015; 116: 17-19
49. Choi JH, Jonsson-Schmunk K, Qiu X, et al. A single dose respiratory recombinant adenovirus-based vaccine provides long-term protection for non-human primates from lethal Ebola infection. Mol Pharm 2014. [Epub ahead of print]
50. RSV001-A new vaccine to prevent severe viral chest infections. Available from: https://clinicaltrials.gov/ct2/show/NCT01805921
51. Sullivan N, Yang ZY, Nabel GJ. Ebola virus pathogenesis: implications for vaccines and therapies. J Virol 2003; 77 (18): 9733-7
52. Martin JE, Sullivan NJ, Enama ME, et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol 2006; 13 (11): 1267-77
53. Roy MJ, Wu MS, Barr LJ, et al. Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 2000; 19 (7-8): 764-78
54. Moorthy VS, McConkey S, Roberts M, et al. Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine 2003; 21 (17-18): 2004-11
55. Moorthy VS, Imoukhuede EB, Keating S, et al. Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men. J Infect Dis 2004; 189 (12): 2213-19
56. Fallaux FJ, Bout A, van der Velde I, et al. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther 1998; 9 (13): 1909-17
57. Ledgerwood JE, Costner P, Desai N, et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine 2010; 29 (2): 304-13
58. Sarwar UN, Costner P, Enama ME, et al. Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial. J Infect Dis 2015; 211 (4): 549-57
59. Zhu FC, Hou LH, Li JX, et al. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet 2015; 385: 2272-9
60. Barnes E, Folgori A, Capone S, et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 2012; 4 (115): 115-111
61. Ledgerwood JE, DeZure AD, Stanley DA, et al. Chimpanzee adenovirus vector Ebola vaccine-preliminary report. N Engl J Med 2014. [Epub ahead of print]
62. Rampling T, Ewer K, Bowyer G, et al. A Monovalent Chimpanzee Adenovirus Ebola Vaccine-Preliminary Report. N Engl J Med 2015. [Epub ahead of print]
63. Sullivan NJ, Martin JE, Graham BS, Nabel GJ. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol 2009; 7 (5): 393-400
64. Sullivan NJ, Hensley L, Asiedu C, et al. CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med 2011; 17 (9): 1128-31
65. Regules JA, Beigel JH, Paolino KM, et al. A recombinant vesicular stomatitis virus Ebola vaccine-preliminary report. N Engl J Med 2015. [Epub ahead of print]
66. Agnandji ST, Huttner A, Zinser ME, et al. Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe-Preliminary Report. N Engl J Med 2015. [Epub ahead of print]
67. Shuchman M. Ebola vaccine trial in west Africa faces criticism. Lancet 2015; 385: 1933-4
68. Phase 1 Trial of Ebola Vaccine in Mali. Available from: https://clinicaltrials.gov/ct2/show/NCT02267109
69. A clinical trial on the candidate vaccine cAd3-EBOZ in healthy adults in Switzerland. Available from: https://clinicaltrials.gov/ct2/show/NCT02289027
70. A Safety and immunogenicity study of heterologous prime-boost ebola vaccine regimens in healthy participants. Available from: https://clinicaltrials.gov/ct2/show/NCT02313077
71. Clinical trial of the cAd3-EBO and cAd3-EBOZ Ebola vaccines in healthy adults in uganda. Available from: https://clinicaltrials.gov/ct2/show/NCT02354404
72. Partnership for research on ebola vaccines in liberia (PREVAIL). Available from: https://clinicaltrials.gov/ct2/show/NCT02344407
73. A study to evaluate the safety and immunogenicity of heterologous prime-boost ebola vaccine regimens in healthy participants. Available from: www.clinicaltrials.gov/ct2/show/NCT02376426
74. A Safety and immunogenicity study of heterologous and homologous prime-boost ebola vaccine regimens in healthy participants. Available from: https://clinicaltrials.gov/ct2/show/NCT02325050